The impact of childhood acute rotavirus gastroenteritis on the parents’ quality of life: prospective observational study in European primary care medical practices

BMC Pediatrics

Katsiaryna Holl⁴  Jean-Yves Pirçon⁴  Nadia Meyer⁴  Montse Soriano-Gabarro¹  Juliette Meunier²  Benoit Arnould²  Luigi Cantarutti⁵  Marian Patrzalek⁶  Javier Diez Domingo³ 

[1] Bayer Schering Pharma AG, Berlin, Germany;MAPI Consultancy, Lyon, France;Centro Superior de Investigacion en Salud Publica (CSISP), Area de Investigación en Vacunas, Avda Catalunya 21, Valencia, 46020, Spain;GlaxoSmithKline Biologicals, Wavre, Belgium;Pedianet network, Padova, Italy;Nzoz Promed, Pediatric Clinic, Kielce, Poland

关键词: Quality of life;    Paediatric;    Gastroenteritis;    Rotavirus;   

Others  :  1170787
DOI  :  10.1186/1471-2431-12-58

 received in 2011-12-02, accepted in 2012-05-15,  发布年份 2012

【 摘 要 】

Background

Rotavirus (RV) is the commonest cause of acute gastroenteritis in infants and young children worldwide. A Quality of Life study was conducted in primary care in three European countries as part of a larger epidemiological study (SPRIK) to investigate the impact of paediatric rotavirus gastroenteritis (RVGE) on affected children and their parents.

Methods

A self-administered questionnaire was linguistically validated in Spanish, Italian and Polish. The questionnaire was included in an observational multicentre prospective study of 302 children aged <5 years presenting to a general practitioner or paediatrician for RVGE at centres in Spain, Italy or Poland. RV infection was confirmed by polymerase chain reaction (PCR) testing (n = 264). The questionnaire was validated and used to assess the emotional impact of paediatric RVGE on the parents.

Results

Questionnaire responses showed that acute RVGE in a child adversely affects the parents’ daily life as well as the child. Parents of children with RVGE experience worry, distress and impact on their daily activities. RVGE of greater clinical severity (assessed by the Vesikari scale) was associated with higher parental worries due to symptoms and greater changes in the child’s behaviour, and a trend to higher impact on parents’ daily activities and higher parental distress, together with a higher score on the symptom severity scale of the questionnaire.

Conclusions

Parents of a child with acute RVGE presenting to primary care experience worry, distress and disruptions to daily life as a result of the child’s illness. Prevention of this disease through prophylactic vaccination will improve the daily lives of parents and children.

【 授权许可】

   
2012 Diez-Domingo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Parashar UD, Bresee JS, Gentsch JR, Glass RI: Rotavirus. Emerg Infect Dis 1998, 4:561-570.
• [2]Williams CJ, Lobanov A, Pebody RG: Estimated mortality and hospital admission due to rotavirus infection in the WHO European region. Epidemiol Infect 2009, 137:607-616.
• [3]Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T: Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25:S7-S11.
• [4]Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V: European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008, 46:615-618.
• [5]Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V: European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008, 46(Suppl 2):S38-S48.
• [6]World Health Organization: Meeting of the immunization Strategic Advisory Group of Experts, April 2009–conclusions and recommendations. Wkly Epidemiol Rec 2009, 84:220-236.
• [7]Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De VB: Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004, 23:937-943.
• [8]Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A: Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
• [9]Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
• [10]Gimenez-Sanchez F, Gado-Rubio A, Martinon-Torres F, Bernaola-Iturbe E: Multicenter prospective study analysing the role of rotavirus on acute gastroenteritis in Spain. Acta Paediatr 2010, 99:738-742.
• [11]Diez-Domingo J, Baldo JM, Patrzalek M, Pazdiora P, Forster J, Cantarutti L, Pircon JY, Soriano-Gabarro M, Meyer N: Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. Eur J Pediatr 2011, 170:213-222.
• [12]Iturriza-Gomara M, Kang G, Gray J: Rotavirus genotyping: keeping up with an evolving population of human rotaviruses. J Clin Virol 2004, 31:259-265.
• [13]Kuhne Simmonds M, Armah G, Asmah R, Banerjee I, Damanka S, Esona M, Gentsch JR, Gray JJ, Kirkwood C, Page N, et al.: New oligonucleotide primers for P-typing of rotavirus strains: strategies for typing previously untypeable strains. J Clin Virol 2008, 42:368-373.
• [14]Ruuska T, Vesikari T: Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22:259-267.
• [15]Viala-Danten M, Meunier J, Arnould B: Development and psychometric validation of a new questionnaire measuring the impact of child gastroenteritis on parents. Poster presented at ISPOR, Athens, 8–11 November 2008. Value Health 2008, 11:A526-A527.
• [16]Forster J, Guarino A, Parez N, Moraga F, Roman E, Mory O, Tozzi AE, de Aguileta AL, Wahn U, Graham C, et al.: Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009, 123:e393-e400.
• [17]Senecal M, Brisson M, Lebel MH, Yaremko J, Wong R, Gallant LA, Garfield HA, Ableman DJ, Ward RL, Sampalis JS, et al.: Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): a prospective community-based study. Can J Infect Dis Med Microbiol 2008, 19:397-404.
• [18]Brisson M, Senecal M, Drolet M, Mansi JA: Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010, 29:73-75.
• [19]Brooks R: EuroQol: the current state of play. Health Policy 1996, 37:53-72.
• [20]Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108.
• [21]Mast TC, Muro-Mercon C, Kelly CM, Floyd LE, Walter EB: The impact of rotavirus gastroenteritis on the family. BMC Pediatr 2009, 9:11. BioMed Central Full Text
• [22]Gimenez-Sanchez F, Delgado RA, Martinon TF, Asensi BF, Miranda VM, Gomez Llorente JL, Alfayate MS, Carmona MA, Romero GJ, Crespo HM, et al.: Family impact of rotavirus gastroenteritis in children under two years. An Pediatr (Barc) 2008, 69:515-520.
• [23]Van der Wielen M, Giaquinto C, Gothefors L, Huelsse C, Huet F, Littmann M, Maxwell M, Talayero JM, Todd P, Vila MT, et al.: Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. BMC Fam Pract 2010, 11:22. BioMed Central Full Text
• [24]Huppertz HI, Forster J, Heininger U, Roos R, Neumann HU, Hammerschmidt T: The Parental Appraisal of the Morbidity of Diarrhea in Infants and Toddlers (PAMODI) survey. Clin Pediatr (Phila) 2008, 47:363-371.